List of Excipients in Branded Drug TEMAZEPAM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
SpecGx LLC	TEMAZEPAM	temazepam	0406-9960	ALCOHOL
SpecGx LLC	TEMAZEPAM	temazepam	0406-9960	BUTYL ALCOHOL
SpecGx LLC	TEMAZEPAM	temazepam	0406-9960	ETHYL ACETATE
SpecGx LLC	TEMAZEPAM	temazepam	0406-9960	FD&C BLUE NO. 1
SpecGx LLC	TEMAZEPAM	temazepam	0406-9960	FD&C RED NO. 3
SpecGx LLC	TEMAZEPAM	temazepam	0406-9960	FERRIC OXIDE RED
SpecGx LLC	TEMAZEPAM	temazepam	0406-9960	GELATIN

Generic Drugs Containing TEMAZEPAM

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	temazepam	0228-2076	D&C YELLOW NO. 10
Actavis Pharma Inc	temazepam	0228-2076	D&C YELLOW NO. 10 ALUMINUM LAKE
Actavis Pharma Inc	temazepam	0228-2076	FD&C BLUE NO. 1 ALUMINUM LAKE
Actavis Pharma Inc	temazepam	0228-2076	FD&C BLUE NO. 2--ALUMINUM LAKE
Actavis Pharma Inc	temazepam	0228-2076	FD&C GREEN NO. 3
Actavis Pharma Inc	temazepam	0228-2076	FD&C RED NO. 40
Actavis Pharma Inc	temazepam	0228-2076	FD&C YELLOW NO. 6

What are the Most Frequently-Used Excipients in TEMAZEPAM?

# Of NDCs	Excipient
59	ALCOHOL
58	AMMONIA
1	AMMONIUM CATION
54	ANHYDROUS LACTOSE
6	BENZYL ALCOHOL
1	BLUE 1
59	BUTYL ALCOHOL

Temazepam Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 5, 2026

Temazepam is an established generic benzodiazepine with limited active-ingredient patent protection and substantial regulatory constraints. Commercial opportunity is concentrated in differentiated oral dosage forms, excipient optimization, supply reliability, and targeted formulations for patients with swallowing difficulty, lactose intolerance, or sensitivity to common colorants. The strongest near-term strategy is a compliant, bioequivalent solid oral product with a simple excipient system rather than an expensive novel-delivery platform.

What is the regulatory and commercial status of temazepam?

Temazepam is an oral benzodiazepine approved for the short-term treatment of insomnia when insomnia causes clinically significant distress or functional impairment. The reference product is Restoril, marketed by Mallinckrodt Pharmaceuticals in the United States. Temazepam is a Schedule IV controlled substance under the federal Controlled Substances Act. The FDA label identifies 7.5 mg, 15 mg, 22.5 mg, and 30 mg capsule strengths, although commercial availability can vary by manufacturer and channel [1, 2].

Attribute	Temazepam position
Active ingredient	Temazepam
Drug class	Benzodiazepine hypnotic
Primary use	Short-term insomnia treatment
Route	Oral
Common dosage form	Capsule
U.S. reference brand	Restoril
Controlled-substance status	Schedule IV
FDA pathway for generics	ANDA, subject to applicable requirements
Biosimilar exposure	None; temazepam is a small molecule
Main commercial market	Generic prescription capsules
Principal differentiation routes	Excipient simplification, dosage-form convenience, supply, packaging, and authorized or branded generic positioning

FDA-approved temazepam products are subject to controlled-substance prescribing, dispensing, recordkeeping, and diversion-control requirements. The FDA label also carries class-wide benzodiazepine risks, including abuse, misuse, addiction, physical dependence, withdrawal reactions, and potentially fatal respiratory depression when combined with opioids [1].

What excipients are used in temazepam capsules?

Temazepam capsule formulations commonly use a conventional hard-gelatin capsule system. The active ingredient is present at a relatively low dose, so excipient selection affects content uniformity, powder flow, capsule fill weight, dissolution, stability, and patient acceptability.

Public labeling for Restoril and generic temazepam products identifies excipient categories that can include lactose, starch, talc, magnesium stearate, gelatin, titanium dioxide, and approved colorants. Exact composition varies by manufacturer and strength. Product-specific labeling must control the formulation description because excipient systems are not interchangeable across suppliers [1, 3].

Excipient category	Typical role in temazepam capsules	Key development issue
Lactose	Diluent and fill-weight builder	Relevant to lactose-intolerant patients and excipient disclosure
Pregelatinized starch or starch	Diluent, binder, and disintegrant	Affects powder flow and dissolution
Magnesium stearate	Lubricant	Excessive concentration or blending can slow dissolution
Talc	Glidant or processing aid	Must be controlled for particle properties and supply consistency
Gelatin	Capsule shell	Animal source, moisture, shell brittleness, and religious or dietary requirements
Titanium dioxide	Opacifier	Regulatory and market-acceptance considerations vary by jurisdiction
FD&C dyes	Strength and product identification	Colorant restrictions and patient preference
Purified water	Capsule-shell processing	Moisture migration and stability control

The simplest development approach is usually a conventional capsule containing temazepam, a compatible diluent, a disintegrant or starch-based filler, and a low-level lubricant. A reduced-excipient formulation can lower supplier count, simplify quality control, and support a cleaner label. It can also create a marketable distinction if the product removes lactose, selected dyes, or animal-derived gelatin.

Which excipient strategies offer the strongest commercial value?

Lactose-free temazepam

A lactose-free capsule is one of the most practical differentiation opportunities. Lactose is widely used in oral solid products because it is inexpensive, established, and easy to process. Removing lactose may appeal to patients who avoid it and to institutional buyers seeking simplified excipient profiles.

A lactose-free formulation can use microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch, or a combination of these materials. Selection must account for temazepam dose uniformity, powder segregation, lubrication sensitivity, and dissolution.

The commercial value is incremental rather than exclusive. A lactose-free claim would not generally create meaningful patent protection by itself. It would compete through labeling, pharmacy substitution policy, contracting, and patient or prescriber preference.

Dye-free and titanium-dioxide-free capsules

Colorants help distinguish capsule strengths, but they increase formulation complexity and can create jurisdiction-specific regulatory issues. A white, natural, or uncolored capsule can support a simplified excipient label. Titanium dioxide restrictions and consumer scrutiny have increased interest in alternative capsule-shell systems in some markets.

A dye-free product is most attractive when paired with clear strength marking, tamper-evident packaging, and reliable visual differentiation. The main risks are patient confusion between strengths and reduced brand recognition at the dispensing level.

Vegetarian or HPMC capsules

Hydroxypropyl methylcellulose, or HPMC, capsules can address vegetarian, dietary, religious, and animal-origin concerns. HPMC shells may also provide a platform for moisture-sensitive products, although shell behavior differs from gelatin in disintegration, mechanical properties, and fill performance.

A vegetarian temazepam capsule can command a modest premium in selected channels, especially in institutional, international, and direct-to-consumer pharmacy markets. It must still demonstrate equivalent pharmaceutical performance to the reference product and meet capsule-shell quality specifications.

Low-moisture formulations

Temazepam products require control of moisture, capsule-shell interactions, and degradation pathways. A low-moisture excipient system can improve physical stability, but the benefit depends on actual compatibility data. Excessive desiccation may create shell brittleness or fill-content variability.

Commercially, a formulation with improved stability is more valuable where it enables longer shelf life, wider storage conditions, or fewer product complaints. The claim must be supported by stability studies under ICH conditions and by the approved labeling.

Taste-masked and orally disintegrating products

Temazepam is administered at bedtime, and some patients have difficulty swallowing capsules. An orally disintegrating tablet, orally disintegrating mini-tablet, or rapidly dispersible dosage form could target this population.

The commercial barrier is higher than for a conventional capsule. An ODT would require control of taste, dose uniformity, mechanical strength, disintegration, moisture sensitivity, packaging, and bioequivalence. Because temazepam is controlled, unit-dose packaging and diversion controls are important.

A taste-masked product also creates a potential misuse concern because faster disintegration or easier administration could affect abuse patterns. The formulation should not be marketed as safer or less addictive without specific evidence and regulatory support.

What formulations are protected by temazepam patents?

Temazepam is an old small-molecule drug, and core composition-of-matter protection has expired. The commercial reference product does not rely on a meaningful remaining active-ingredient patent barrier in the U.S. Generic temazepam capsules are widely available, indicating that ANDA approval has already overcome the principal regulatory barrier for conventional products.

Potentially protectable subject matter in a new temazepam product could include:

• A novel excipient ratio that produces a demonstrated dissolution or stability advantage.
• A specific controlled-release profile.
• A novel capsule-shell composition.
• A taste-masking system.
• A unit-dose or tamper-resistant package.
• A manufacturing process that reduces degradation or improves content uniformity.
• A method of use directed to a narrower patient population or dosing schedule.

The patentability of these features depends on novelty, non-obviousness, written description, enablement, and claim scope. A simple substitution of lactose with microcrystalline cellulose, mannitol, or another standard diluent is likely to face an obviousness challenge unless supported by an unexpected technical effect.

When does temazepam lose exclusivity?

Temazepam has already lost U.S. market exclusivity for conventional oral capsules. FDA generic products are marketed, and the reference product is no longer protected by the type of active patent or regulatory exclusivity that would prevent routine generic competition.

Exclusivity element	Current commercial implication
Composition-of-matter patent	Expired for the historical active ingredient
Original brand exclusivity	Expired
New chemical entity exclusivity	Not commercially relevant today
Biosimilar exclusivity	Not applicable
Formulation exclusivity	Possible only for a separately protected, later-developed product
Method-of-use protection	Potentially relevant only for a specific later-approved indication
Generic entry	Already established for conventional capsules

The exact patent position must be assessed by jurisdiction and product. A U.S. Orange Book review should distinguish between historical Restoril listings, currently relevant patents, and patents associated with unrelated or later formulations. A generic applicant should not assume that an old branded product has no listed patents without checking the current FDA Orange Book and relevant FDA approval records [4].

What is the Orange Book status of temazepam?

The Orange Book is relevant to temazepam because it identifies approved reference products, therapeutic equivalence evaluations, and applicable listed patents and exclusivities. Conventional temazepam capsules are subject to the ANDA framework. Generic applicants must address any listed patent certifications required under Section viii or Paragraph IV procedures, depending on the patent claims and proposed labeling [4, 5].

For a conventional temazepam capsule, the main regulatory pathway is likely:

1. Identify the applicable reference-listed drug.
2. Match strength, route, dosage form, and conditions of use.
3. Demonstrate pharmaceutical equivalence.
4. Demonstrate bioequivalence under FDA requirements.
5. Submit labeling and controlled-substance compliance information.
6. Address listed patents through the applicable certification.
7. Establish manufacturing, packaging, serialization, and distribution controls.

A reformulated product may require a different regulatory strategy if it is not therapeutically equivalent to the reference product. A 505(b)(2) application could be relevant for a novel dosage form or delivery system, but it would bring additional clinical, pharmacokinetic, and patent-certification considerations.

Which companies are challenging temazepam exclusivity?

Generic temazepam competition has already been established by multiple manufacturers. The relevant competitive set includes generic capsule suppliers, contract manufacturers, specialty-pharmacy suppliers, and the Restoril brand or authorized-brand channel.

Publicly visible commercial competition is more important than current Paragraph IV activity because the conventional product is already genericized. A new entrant would compete against approved generic suppliers rather than waiting for first generic launch.

The principal competitive variables are:

• Product availability by strength.
• Wholesaler and group-purchasing contracts.
• Controlled-substance distribution capability.
• Reliable API sourcing.
• Recalls and back-order history.
• Capsule-shell and excipient supply continuity.
• Wholesale acquisition cost.
• Pharmacy substitution status.
• Packaging and inventory controls.

What patent litigation affects temazepam?

Temazepam does not present the litigation profile of a recently approved branded medicine. Core generic entry has occurred, and the commercial market is mature. The more relevant litigation risks for a new product would involve:

• Patent infringement claims on a novel delivery system.
• Trade dress or trademark disputes involving capsule appearance.
• API manufacturing processes.
• Formulation patents for modified release or taste masking.
• Contract disputes involving controlled-substance distribution.
• Product-liability claims involving dependence, misuse, respiratory depression, or concomitant opioid use.

A conventional immediate-release generic capsule is less likely to generate material formulation patent litigation than a modified-release, ODT, abuse-deterrent, or specialty-packaged product. The absence of a strong active-ingredient patent barrier does not eliminate freedom-to-operate issues around later-developed dosage forms.

What Paragraph IV challenges and generic launch scenarios exist?

The conventional generic launch scenario is already established. A new applicant could pursue one of four commercial paths.

Launch scenario	Regulatory route	Commercial profile	Main risk
Standard immediate-release capsule	ANDA	Lowest development cost and fastest market entry	Price erosion and crowded supply base
Lactose-free or dye-free capsule	ANDA if therapeutically equivalent	Moderate differentiation	Limited pricing power
Vegetarian HPMC capsule	ANDA or alternative pathway depending on differences	Premium niche opportunity	Shell-performance and demand uncertainty
ODT or rapidly dispersible product	ANDA, 505(b)(2), or other applicable pathway	Higher differentiation	Bioequivalence, abuse, and development cost
Modified-release product	Likely 505(b)(2) or new product strategy	Potentially higher value	Clinical and patent risk

A Paragraph IV strategy is most relevant if the proposed product relies on a later-listed formulation or method-of-use patent. For the old immediate-release capsule, market entry does not depend on defeating a valuable core patent estate.

How strong is the temazepam patent estate?

The core temazepam patent estate is weak from a blocking perspective because the active ingredient and conventional capsule technology are mature. The strongest potential protection lies in product-specific improvements rather than the molecule itself.

Patent category	Relative strength	Commercial assessment
Active ingredient	Low	Historical protection has expired
Conventional immediate-release capsule	Low	Standard excipients are widely known
Novel excipient combination	Low to moderate	Requires unexpected technical benefit
ODT or taste-masked product	Moderate	Stronger if performance is difficult to reproduce
Modified release	Moderate to high	Depends on release mechanism and claim breadth
Abuse-deterrent formulation	Moderate	Requires meaningful resistance and evidence
Manufacturing process	Moderate	Useful if process is difficult to design around
Packaging and dispensing system	Low to moderate	May protect implementation, not the medicine broadly

A patent strategy should focus on claims that connect composition to measurable performance. Broad claims covering any temazepam formulation are unlikely to provide durable protection. Narrow claims directed to dissolution windows, stability thresholds, capsule-shell parameters, or validated manufacturing controls have a better chance of surviving examination and enforcement.

What manufacturing and IP barriers affect commercial entry?

The main manufacturing barrier is controlled-substance compliance rather than chemical synthesis. A supplier must manage procurement, storage, inventory reconciliation, security, shipment controls, and diversion monitoring. API supply qualification is also important because benzodiazepine supply chains can face regulatory scrutiny and allocation constraints.

Key technical controls include:

• Blend uniformity at low active-drug loading.
• Control of particle-size distribution.
• Prevention of segregation during capsule filling.
• Lubricant-level control.
• Dissolution matching to the reference product.
• Moisture control for both fill material and capsule shell.
• Stability in commercial packaging.
• Strength identification and packaging differentiation.
• Serialization and controlled-substance distribution records.

An excipient strategy that uses common, multi-source materials can reduce supply risk. A formulation dependent on one specialty capsule shell, a single colorant supplier, or a narrow-grade excipient can create avoidable manufacturing exposure.

How does temazepam compare with competing insomnia drugs?

Temazepam competes with generic zolpidem, eszopiclone, zaleplon, doxepin, suvorexant, lemborexant, and nonprescription sleep products. Its commercial disadvantages include benzodiazepine-class safety concerns, controlled-substance status, dependence risk, and regulatory scrutiny. Its advantages include physician familiarity, established dosing, low generic cost, and a known capsule platform.

Product category	Patent and exclusivity profile	Commercial implication
Temazepam generic	Mature, largely commoditized	Low price, high availability
Zolpidem generic	Mature generic market	Strong direct price competition
Eszopiclone generic	Mature but differentiated by duration and formulation	Competes for chronic insomnia use
Doxepin generic	Non-controlled alternative	Appeals to risk-averse prescribers
Orexin antagonists	Active branded or recently genericizing estates depending on product	Higher price and stronger differentiation
OTC antihistamine products	No prescription controlled-substance barrier	Broad consumer access but tolerability limitations

Temazepam’s best commercial opportunity is not a premium price based solely on the molecule. It is a targeted product that solves a practical problem while maintaining a low-cost generic profile.

What revenue exposure and commercial opportunities exist?

Revenue exposure is tied to market maturity, generic price erosion, and the limited duration of treatment recommended in labeling. A conventional generic capsule can generate volume but usually has low per-unit economics. Margin depends on manufacturing efficiency, supply reliability, purchasing contracts, and avoidance of shortages.

The most credible opportunities are:

1. A lactose-free, dye-free capsule for institutional and specialty-pharmacy channels.
2. A vegetarian HPMC capsule for selected international and retail markets.
3. A robust multi-source excipient platform that reduces supply interruptions.
4. A higher-convenience product for swallowing-impaired patients.
5. A 505(b)(2) formulation with a clinically meaningful pharmacokinetic or adherence advantage.
6. Contract manufacturing or private-label supply for pharmacies and healthcare systems.
7. Packaging designed for controlled-substance accountability and adherence.

The least attractive strategy is an undifferentiated capsule entering a crowded market solely on price. The product would face established suppliers, limited switching costs, and rapid margin compression.

Key Takeaways

• Temazepam is a mature, genericized benzodiazepine with no meaningful remaining core-molecule exclusivity in the U.S.
• Conventional capsules use established excipients such as lactose, starch, magnesium stearate, talc, gelatin, titanium dioxide, and colorants, depending on manufacturer.
• Lactose-free, dye-free, titanium-dioxide-free, and vegetarian capsules offer the clearest low-risk differentiation.
• Novel excipient claims require measurable technical advantages because standard excipient substitutions are vulnerable to obviousness challenges.
• ODT, taste-masked, modified-release, and abuse-deterrent products offer more differentiation but carry higher regulatory, clinical, and patent risk.
• The main operational barrier is controlled-substance manufacturing and distribution compliance.
• Commercial returns from a standard capsule are likely to depend on supply reliability and contract access rather than patent exclusivity.
• Temazepam has no biosimilar risk because it is a small-molecule drug.
• A new entrant should prioritize formulation simplicity, multi-source excipients, bioequivalence, controlled-substance controls, and a defensible patient-centered product attribute.

FAQs

Can a lactose-free temazepam capsule obtain a separate patent?

It may be patentable only if the formulation produces a novel and non-obvious technical result. A routine replacement of lactose with a known diluent is unlikely to create strong patent protection without unexpected stability, dissolution, manufacturability, or bioavailability data.

Is temazepam suitable for an abuse-deterrent formulation?

It is technically suitable for investigation because temazepam is a controlled benzodiazepine. The commercial case would require evidence that the formulation meaningfully limits crushing, extraction, rapid release, or other misuse pathways without compromising therapeutic performance.

Would an HPMC capsule require a new FDA approval?

The regulatory route depends on whether the product remains pharmaceutically equivalent and bioequivalent to the reference product. A conventional shell substitution may fit an ANDA strategy, but material differences in performance, labeling, or release could require additional regulatory support.

Can temazepam be developed as an oral solution?

An oral solution is technically feasible but commercially sensitive. Solubility, chemical stability, dose uniformity, preservative selection, taste, packaging, and controlled-substance diversion risk would require substantial development work.

Does temazepam have biosimilar competition?

No. Biosimilar regulation applies to biological products. Temazepam is a chemically synthesized small molecule and competes through generic-drug pathways, including ANDAs and, for certain novel products, potentially 505(b)(2) applications.

References

1. U.S. Food and Drug Administration. (2023). Restoril (temazepam) capsules prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

3. National Library of Medicine. (2024). DailyMed: Temazepam capsule labeling. https://dailymed.nlm.nih.gov/dailymed/

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

5. U.S. Food and Drug Administration. (2024). Guidance for industry: Applications covered by section 505(b)(2). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applications-covered-section-505b2)